FY2027 EPS Estimates for Amgen Boosted by Erste Group Bank

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at Erste Group Bank upped their FY2027 earnings per share (EPS) estimates for Amgen in a report issued on Tuesday, March 24th. Erste Group Bank analyst H. Engel now expects that the medical research company will earn $23.60 per share for the year, up from their previous forecast of $23.56. Erste Group Bank currently has a “Buy” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period in the previous year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS.

Several other brokerages also recently weighed in on AMGN. HSBC restated a “buy” rating and issued a $425.00 target price on shares of Amgen in a research note on Wednesday, December 10th. Oppenheimer set a $400.00 price objective on shares of Amgen and gave the company an “outperform” rating in a research report on Thursday, January 29th. Royal Bank Of Canada raised their target price on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. Rothschild & Co Redburn lifted their target price on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Finally, BMO Capital Markets boosted their price target on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $354.60.

Amgen Trading Down 1.2%

AMGN opened at $348.77 on Thursday. The firm’s 50 day moving average is $362.59 and its 200-day moving average is $329.87. Amgen has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm has a market capitalization of $188.01 billion, a P/E ratio of 24.51, a P/E/G ratio of 3.50 and a beta of 0.45.

Institutional Trading of Amgen

Several institutional investors have recently added to or reduced their stakes in the business. Norges Bank bought a new position in shares of Amgen during the fourth quarter valued at approximately $2,164,162,000. Capital World Investors lifted its holdings in shares of Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the last quarter. State Street Corp boosted its position in Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after purchasing an additional 1,287,310 shares during the period. Geode Capital Management LLC boosted its position in Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after purchasing an additional 1,035,779 shares during the period. Finally, Amundi grew its stake in Amgen by 41.1% during the 4th quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock worth $1,111,854,000 after buying an additional 988,856 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s dividend payout ratio (DPR) is 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.